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Mephenytoin (3-methyl-5-ethyl-5-phenylhydantoin) was first introduced in 1945 as an anticonvulsant drug (1).
Early studies showed that mephenytoin was effective in control of grand mat and focal seizures (2) (3) (4) (5) . Although mephenytoin causes fewer side effects such as nausea, ataxia, and gum hyperplasia than does phenytomn, the incidence of serious dermatitis, agranulocytosis, anemias, and hepatitis is greater in patients being treated with mephenytoin for seizure control (6) . Fatal cases of aplastic anemia have been also reported (6, 7) . In spite of these side effects, Troupin et al. (7) recommend a wider use of this drug by patients in whom seizures are difficult to control.
Mephenytomn is metabolized by demethylation to desmethylmephenytoin (5-ethyl-5-phenylhydantoin), an active metabolite (8). To correlate clinical effects and drug concentration in serum, one must measure both mephenytoin and desmethylmephenytoin (7) . The therapeutic concentration for the two together reportedly is 15-40 mg/L (9).
The fact that therapy with mephenytoin has been associated with relatively high incidences of serious side effects has led to its use mainly in patients with severe grand mal seizures which are resistant to less toxic agents, and has motivated us to develop an assay for mephenytoin and desmethylmephenytoin that is appropriate for routine use in the clinical toxicology laboratory.
Several have been reported (14, 15) , and our method is based on these observations. The method involves extraction of mephenytoin and desmethylmephenytoin with charcoal and off-column derivatization of the drugs followed by gas-chromatographic determination.
Materials and Methods

Apparatus
We useda dual column Hewlett-Packard 
Minutes Minutes
Add 1 mL ofserum orstandard,1 mL ofextraction buffer, and about 20 mg of charcoal to 15 X 125mm culture tubewith a poly(tetrafluoroethylene)-lined cap. (The amount of charcoal added to each tube was visually estimated after an initial weighing.) Vortex-mix the mixture for 15s and then centrifuge for 5 mm at 1000 X g. Aspirate and discard the supernate. To the charcoal, add 2 mL of dichloromethaneand vortex-mix for30s.Decant thedichloromethane intoa clean 15-mL glass centrifuge tube and evaporateitina stream ofair, with the tube ina water bath at 55 #{176}C. To the residueadd 50 ML of pentyliodidein N,N-dimethylacetamide and 25 LL of tnmethylphenylammonium hydroxide in N,N-dimethylacet-
Minutes
amide.Vortex-mixfor5s and allowtoreact for10mm at room temperature.Then add 0.5 mL of cyclohexane/dichloromethane (95/5 by vol)solution to precipitate the excessof derivatizing reagents. Centrifuge for 5 mm at 1000 X g. Decant the supernate into a clean 13 X 100 mm culture tube and evaporate as before. Dissolve theresidue in50 ML ofmethanol and inject 1 ML intothegas chromatograph.
Results and Discussion
Figure 1 depicts some representative chromatograms of serum takenthroughour method. The separation ofcaffeine from mephenytomn is incomplete but adequate, as shown in Figure 1C . Table 1 lists absolute and relative retention times of drugs most frequently prescribed for patients undergoing anticonvulsant therapy. None of these drugs interferes in the present method.
Quantitation of mephenytoin and desmethylmephenytoin is based on the relative peak height ratios with 5-methyl-5-phenylhydantoin as the internal standard. Figure 2 We evaluated the accuracy of the method by a recovery study. 1)rug-free serum was supplemented with mephenytoin and desmethylmephenytoin at two different drug concentrations and the recovery calculated (Table 3) ,
We examined the correlation between our method and the method of Friel and Troupin (12) . These authors kindly supplied us wit.h 10 patients' samples that they had already analyzed for mephenytoin and desmethylmephenytoin according to their published procedure (12). Table 4 shows the correlation of our data with theirs for mephenytoin, desmethylmephenytoin, and the total of both drugs. Figure 3 shows the correlation fortotal drug concentration. The correlation coefficients areall quite satisfactory, but there is a difference for mephenytoin concentration. This may be related to the very low mephenytoin concentration in the sampies that we analyzed; the mean mephenytoin concentration for these 10 samples was 2.4 mg/L. We have measured the recovery by our method inthisrangeand found it to be 97% (Table 3) , which we consider to he satisfactory. We have also assayed standard samples supplied by Friel and Troupin, with excellent results. We cannot explain the discrepancy between the two methods that we have observed for low mephenytoin et rncentrations.
The method that we have presented can be used in routine clinical chemistry laboratory determinations for mephenytoin and desmethylmephenytoin. It is accurate and precise. Using off-column alkylation extends the column life by avoiding injections of deleterious alkylating reagents onto the column. This method has been used in our laboratory for over a year, on a weeklyschedule, with no major problems. 
